lucius卢修斯 来那帕韦钠 LenacapavirHIV-1

来那帕韦钠

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Lenacapavir

老挝国家食药监局批准上市
老挝国家药检所检测认证

Compostiva:

HIV-1

LUCÏUS

Indicaton:
LaciLenseeo,.t hunan immsnodeficiency surs type

PHARMACEUTICALS

antiretrourllo is irdiental fnr he

ws indicated for ihe treatment of Fil .

latection in bezvily frestment-exseren
ang iter curent

LuciLenacap

satety coms iderabinne

*Kes ornuncat dasage-Intiaion vith one of fxo options

Lenacapavir Tablets

FDA批准

Option 1:Day 1-600mg orally (2/300mg tablets).Dnv)

300 mchlf
ma tablets)
Dghon2: Dav 1-600me amllvi5

g orlly (2:300 mg tablets ).Dnv 2

Rx Only

Storager in adrvsls

et oa dry place and stono at 20Cto 25°℃
Aeep medicone out of reach of Children. Do not admimster

300mg

Lenacapas ir durina Preenaney and Lactifion

Mafictured aod Marketed by

权威认证

LUQIUS

Thongmang village, Xasthang district, Vientiane
Capiial,Lai
Warsing: Tobe sold by retuil on preserpten

uaced prysicians onby, mnd as directed

5 Tablets

口碑质量

适应症。
来那帕韦钠是一种人类免疫缺陷病毒1型(HIV-1)衣壳抑制剂,与
其他抗逆转录病毒药物联合使用,用于治疗患有多重耐药性HIV-1
感染且目前抗逆转录病毒疗法因耐药性、不耐受性或安全性考虑而
失败的HIV-1感染成人患者。
推荐剂量:
1、方案一:第一天服用600mg(2片),第二天的同一时间服用
600mg(2片);
2、方案二:第一天服用600mg(2片),第二天的同一时间服用
600mg(2片),第3天服用300mg(1片)。